The European Investment Bank has signed a €20 million venture debt facility with BioLamina, the Swedish biotechnology company. The bank signed the loan on 14 April 2026. The financing is under the EIB's venture debt instrument, is backed by InvestEU and sits under the EIB Group's TechEU programme.
BioLamina will use the money to expand and scale production and to fund research and development, including work on animal-free drug safety testing. The EIB said the facility will help the Stockholm company optimise manufacturing, widen its product portfolio and increase its manufacturing footprint. The bank put the total cost of the project at about €53 million. It approved the operation on 26 March. The borrower on the project sheet is BioLamina AB. BioLamina issued its own statement from Sundbyberg on 16 April. The EIB published the transaction on 20 April.
BioLamina develops and manufactures laminin cell-culture materials. It was founded in 2008 by Karl Tryggvason, a professor at the Karolinska Institutet, and his son Kristian Tryggvason. The company is headquartered in Stockholm. Klaus Langhoff-Roos is chief executive.
Lauxera Capital Partners invested €17 million in BioLamina on 12 September 2023 through its Lauxera Growth I fund, joining majority owner Bure Equity, Northislet and the founders. BioLamina's site lists Bure Growth as the largest shareholder, with 51.7 per cent, followed by Lauxera (16.2 per cent), the Tryggvason family (15.3 per cent) and North Islet (14.3 per cent). Bure Equity's 2026 interim reports confirm the 51.7 per cent holding through wholly owned Bure Growth.
The EIB describes the loan as direct, equity-type financing under its venture debt instrument, long-term support for innovative, fast-growing companies that complements venture capital and other equity while limiting immediate dilution for existing shareholders. It says typical tickets run from €10 million to €50 million for European SMEs and mid-caps that have already raised professional equity. Vice-president Karl Nehammer said backing BioLamina would help life-sciences innovation scale in Europe. Langhoff-Roos said the financing allows the company to expand its technology and manufacturing capabilities.
The operation is backed by InvestEU, the EU programme that uses a €26.2 billion budget guarantee to crowd public and private capital into policy-priority projects. The EIB Group is the main implementing partner. The bank said the loan contributes to InvestEU's research, development and innovation objective and to the wider BioTechEU initiative.